Moss Gregory S. 4
4 · Evommune, Inc. · Filed Jun 1, 2026
Research Summary
AI-generated summary of this filing
Evommune (EVMN) Gregory S. Moss Exercises Options, Sells 14,223 Shares
What Happened
Gregory S. Moss, Evommune’s Chief Business & Legal Officer, exercised 14,223 stock options and immediately sold the 14,223 resulting shares on May 28, 2026. The options were exercised at an aggregate cost of $24,321 (exercise price $1.71 per share) and the shares were sold at a weighted average price of $22.83 per share for aggregate proceeds of approximately $324,711. The filing also reports the derivative instrument as disposed (reported at $0), reflecting the option conversion/settlement.
Key Details
- Transaction date: 2026-05-28; Form 4 filed 2026-06-01 (appears timely — within two business days).
- Exercise: 14,223 shares acquired at $1.71 per share (total $24,321).
- Sale: 14,223 shares sold at a weighted average price of $22.83 per share (total ≈ $324,711); sale prices ranged from $22.50 to $23.42.
- Derivative: 14,223 reported as disposed at $0 consistent with conversion of the option.
- Shares owned after transaction: Not specified in the provided filing.
- Notable footnotes: Transactions were made pursuant to a Rule 10b5-1 trading plan adopted Feb 26, 2026 (F1); securities are held by a family trust of which Moss is trustee and he disclaims beneficial ownership except for pecuniary interest (F3); option vesting schedule disclosed (F4).
Context
This was effectively a cashless exercise and immediate sale under a pre-established 10b5-1 plan, which is commonly used to automate insider sales and reduce questions about timing. The 10b5-1 plan and trust holding are disclosed in the filing, so the activity appears structured rather than a spontaneous market-timing decision.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-05-28$1.71/sh+14,223$24,321→ 75,058 total - Sale
Common Stock
[F1][F2]2026-05-28$22.83/sh−14,223$324,711→ 60,835 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
[F1][F4]2026-05-28−14,223→ 47,845 totalExercise: $1.71Exp: 2034-03-21→ Common Stock (14,223 underlying)
- 3,175(indirect: By Trust)
Common Stock
[F3]
Footnotes (4)
- [F1]The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026.
- [F2]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F3]The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
- [F4]One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.